Ultragenyx has fully randomized 129 patients aged 4–17 with full maternal UBE3A gene deletion in the global Phase 3 Aspire study across 28 sites, and has now dosed the first patient in Aurora, a roughly 60‑participant, multi‑cohort trial that broadens GTX‑102 (apazunersen) testing across ages 1 to under 65 and across non‑deletion genotypes. Aurora’s four cohorts use age- and genotype‑tailored endpoints: Bayley‑4 cognitive raw score in deletion-type patients ≥1 to <4 years, and the Multi‑domain Responder Index (MDRI) for UPD/ICD genotypes aged ≥4 to <18, all adult genotypes aged ≥18 to <65, and UBE3A mutation patients aged ≥4 to <18. Cohorts A, B, and C are single‑arm; Cohort D (mutation) randomizes 2:1 to GTX‑102 versus no treatment with crossover at Week 24. All cohorts have a 48‑week primary efficacy period, with options for long‑term extension. The core development is straightforward: Ultragenyx has opened Aurora to extend efficacy and safety evidence for its intrathecal antisense oligonucleotide beyond the deletion‑only, pediatric focus of Phase 3 Aspire. The design allows enrollment across genotypes and age bands, and includes countries or regions not covered in Aspire. The structure blends single‑arm baskets where external or intra‑patient control may be acceptable, with a small randomized segment to introduce a concurrent comparator in a genotype likely to be scrutinized separately. Strategically, this is a label‑shaping and market‑access hedge. A positive Aspire readout could support approval in deletion‑type children, but payers and regulators increasingly expect evidence of generalizability across genetic subtypes and life stages for neurodevelopmental disorders. Aurora’s basket approach is a practical response to rarity and heterogeneity, while the genotype‑specific endpoints reflect divergent developmental trajectories. The 2:1 randomization with early crossover balances the need for controlled data against recruitment realities in a community with no approved disease‑modifying therapies. Given historical safety attention around intrathecal ASOs, a broad age span—including adults—also builds a safety narrative that can de‑risk longer‑term dosing and inform labeling. Operationally, Aurora will concentrate execution in specialized neurology sites capable of intrathecal administration in young children and adults, with the attendant anesthesia/sedation, peri‑procedural monitoring, and caregiver logistics. Rater training and consistency will be non‑trivial: Bayley‑4 requires pediatric neurodevelopmental expertise, while MDRI implementation and interpretation must be harmonized across geographies to avoid signal dilution. The subprotocol structure by cohort adds complexity for CROs and sites in screening, genotype confirmation, scheduling, and data capture. The no‑treatment arm may still introduce enrollment friction, but a Week 24 crossover should mitigate drop‑outs and caregiver reluctance. The immediate watch list is clear. Aspire’s topline is slated for the second half of 2026; alignment between Aspire’s outcomes and Aurora’s MDRI/Bayley‑4 responses will shape how much of Aurora can be leveraged for labeling versus relegated to supportive evidence or post‑marketing commitments. Safety will be tracked closely, particularly procedure‑related events and any neurologic adverse events over the 48‑week window and into extension. Regulators will weigh the sufficiency of single‑arm data for UPD/ICD and adult cohorts; Ultragenyx’s Breakthrough and PRIME statuses may facilitate iterative advice but will not relax evidentiary standards around clinically meaningful, multi‑domain change. From an execution standpoint, sustained site performance in intrathecal delivery and rater reliability will be as determinative as biology. The broader tension is whether a rare‑disease, basket‑style program can satisfy expectations for genotype‑inclusive efficacy while maintaining operational control across disparate endpoints and regions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
